Company profile
SANA BIOTECHNOLOGY, INC.
NASDAQ:SANABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PERSICABTAGENE LEMGEDLEUCEL | phase1 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06285422 | phase1 | active_not_recruiting | 2024-04-18 | 2025-12-01 | Sana Biotechnology | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) |
| NCT06294236 | phase1 | active_not_recruiting | 2024-04-29 | 2027-12-01 | Sana Biotechnology | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) |
| NCT05878184 | phase1 | active_not_recruiting | 2023-05-02 | 2025-11-04 | Sana Biotechnology | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) |
FDA applications (0)
No records yet.